The contribution of genetic predisposition to pediatric cancer: a study integrating extensive phenotyping and state of the art genotyping.

Completed

• Conditions: childhood tumors; pediatric cancer; 10027664; 10027656

• Registration Number: NL-OMON52506
• Lead Sponsor: Prinses Máxima Centrum voor Kinderoncologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 843

Inclusion Criteria

Inclusion criteria for the main study PrediCT:
- Children (age < 19 years) newly diagnosed with cancer or neoplasms at the
Princess Máxima Center (in a period
of three years)
- Written informed consent (by patient when aged 16 years or older, by patient
and parent(s) when aged 12-16
years, by parent(s) when younger than 12 years)

Additional inclusion criteria for REFLECT:
- Consent for participation in PrediCT
- Written informed consent for REFLECT. This can include:
• Parents (of children 0-19 years)
• Children aged 12-16 years (additional consent by their parents needed)
• Children aged 16-19 years.

Additional inclusion criteria for the Hemato add-on study:
- Consent for participation in PrediCT
- Children (age < 19 years) diagnosed with hematological malignancies
(including myelodysplastic syndromes) at the Princess Máxima Center
- Written informed consent for the Hemato add-on study (by patient when aged 16
years or older, by patient and parent(s) when aged 12-16 years, by parent(s)
when younger than 12 years).

Exclusion Criteria

Children and/or their parents who don't want to know the results of the DNA
test (pediatric cancer gene panel
analysis).
Additional exclusion criterion for REFLECT: Insufficient proficiency in Dutch.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Pediatric cancer predisposition syndromes diagnoses (molecular and/or<br /><br>clinical). We will compare the number of cancer predisposition syndromes<br /><br>diagnosed by the genotype first approach (molecular diagnosis based on WES<br /><br>panel analysis) to the phenotype first approach (clinical diagnosis and/or<br /><br>molecular diagnosis based on targeted tests). </p><br>